The HER2CLIMB-02 results could also be good news for Roche, which has seen its ADC come under strong competitive pressure from AstraZeneca and Daiichi Sankyo's rival HER2 ADC Enhertu (trastuzumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback